Ebere Azubuike, MD
Family Medicine · Dallas, TXNPI 1275738874
Payments from drug & device makers
Across 168 payments — averaging $11,317 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.1M
- Genentech, Inc.$813K
- Novartis$25K
- Boehringer Ingelheim$231
- Pfizer$221
- Novo Nordisk$140
- plus $856 from 18 others
Across 3 payments — averaging $556.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$1,466100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 9 | $1,062,160 |
| Genentech, Inc. | 76 | $812,547 |
| Novartis | 3 | $25,023 |
| Boehringer Ingelheim | 12 | $231 |
| Pfizer | 13 | $221 |
| Novo Nordisk | 8 | $140 |
| Lilly USA, LLC | 8 | $118 |
| Abbott | 5 | $96 |
| GSK | 4 | $87 |
| AstraZeneca | 5 | $83 |
| Hologic Sales And Service, LLC | 3 | $67 |
| Dexcom, Inc. | 4 | $66 |
| Bayer | 3 | $52 |
| Amgen | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $40 |
| Exact Sciences | 2 | $37 |
| Edwards Lifesciences | 1 | $31 |
| Gilead | 1 | $27 |
| Phadia US Inc. | 2 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Intra-sana Laboratories | 1 | $17 |
| RGH Enterprises LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Optos, Inc. | 1 | $14 |
How this compares
$1,901,179 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 177 | $247,980 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $129,607 |
| FarxigaDapagliflozin Propanediol | 103 | $106,950 |
| MounjaroTirzepatide | 57 | $79,748 |
| JardianceEmpagliflozin | 57 | $63,672 |
| EliquisApixaban | 35 | $47,334 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 36 | $39,284 |
| RybelsusSemaglutide | 23 | $31,109 |
| GlyxambiEmpagliflozin/Linagliptin | 30 | $28,462 |
| TrulicityDulaglutide | 15 | $22,277 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $21,116 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 46 | $20,740 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $13,622 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $13,385 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $7,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $140 | $279,089200 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Synjardy Xr | $231 | $152,533148 claims |
| GSKTrelegy Ellipta | $87 | $129,60799 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $83 | $120,572115 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $118 | $104,00084 claims |
| PfizerEliquis | $221 | $47,33435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.